🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — need advice Page 2

SOUL trial preliminary data — need advice

roxy_nash Mon, Mar 23, 2026 at 8:00 PM 11 replies 847 viewsPage 2 of 3
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Mar 23, 2026 at 10:03 PM#6
roxy_nash said:
The gap between trial results and real-world results is consistent and it is not fraud.
roxy_nash said:
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 22 RCTs (n=18,900) found that the trial evidence was associated with a consistent effect size across diverse patient populations[1].

The NNT was 20, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.

Last edited: Mar 24, 2026 at 12:03 AM
32 10TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 29 others
Reply Quote Save Share Report
CryptoCarl
Member
789
3,456
May 2024
Arizona
Mar 23, 2026 at 10:51 PM#7

Following on from Dr.LipidDallas — and this may be the naive question:

What would you measure differently if you were starting again?

Last edited: Mar 24, 2026 at 2:51 AM
33 11MariaRD, AussieAnna, BethLabQueen and 30 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Mar 23, 2026 at 11:39 PM#8
labquiet_amy said:
roxy_nash said: ...regarding the trial evidence...

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 12,000 GLP-1 users vs matched controls showed reduced MI incidence (HR 0.78) over 3 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
34 12Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 31 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Mar 24, 2026 at 12:27 AM#9

Closing the loop on my own question.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

Last edited: Mar 24, 2026 at 6:27 AM
35 13Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 32 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Mar 24, 2026 at 4:18 AM#10
Dr.BariatricHTX said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.82 (95% CI 0.69-0.82), I²=40%. This is a robust and consistent effect.

5 3TomFromTexas, mike.trainer_LA, sarah_nash92 and 2 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register